All In Biotech

Drug Trial Radar · NCT05327530

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 256 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

256

Actual

Start

Aug 17, 2022

Primary completion

Jun 20, 2025

Study completion Jan 22, 2027

Sponsor

Sponsor type
Industry
Collaborators
Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
First posted
Apr 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.

Conditions

  • Locally Advanced or Metastatic Urothelial Carcinoma

Interventions

  • AvelumabDrug

    Participants received intravenous infusion of Avelumab at a dose of 800 mg once every 2 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.

  • Sacituzumab Govitecan (SG)Drug

    Participants received intravenous infusion SG at dose of 10 mg/kg of bodyweight once a week on Day 1 and 8 of each 21-daytreatment cycles until unacceptable toxicity, withdraw consent or initiation of a new treatment.

  • M6223Drug

    Participants intravenous infusion of M6223 at dose of 1600 mg once every 2 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.

  • NKTR-255Drug

    Participants intravenous infusion of NKTR-255 at a dose of 3 mcg/kg of body weight once every 4 weeks until unacceptable toxicity, withdraw consent or initiation of a new treatment.

  • JB100Drug

    As per the Clinical Study Protocol, the control group (avelumab alone) was extended by data from an external control, i.e. the JAVELIN Bladder 100 study (JB100) (NCT02603432). Participants received an intravenous infusion of 10 mg/kg of Avelumab along with best supportive care (BSC), on Day 1 and 15 of each 28 days treatment cycle, until confirmed disease progression, participant refusal, lost to follow up, unacceptable toxicity, or study termination by the sponsor, whichever occurred first. BSC was administered asper the treating physician. Participants were followed up until death, end of the study or withdrawal of consent, whichever comes first, regardless of initiation of new anticancer therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + Sacituzumab Govitecan Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
  2. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + M6223 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
  3. Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator - Avelumab + NKTR-255 Versus Avelumab Monotherapy (Avelumab [Control Group] + JB 100 [External Control])Time frame: Time from date of randomization to first documentation of progressive disease (PD) or death, assessed up to 32 months and 12 days (current study) and 41 months (JB100 extended control group)
  4. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment-Related Adverse Events, and AEs of Special Interest (AESIs)Time frame: Up to 32 months and 12 days (Current study) and 61 months and 11 days (JB100 extended control group)

Locations

98 sites in 12 countries. Site status is shown where the registry gives one.

  • Beacon Cancer Care

    Coeur d'Alene, Idaho

  • University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN)

    Kansas City, Kansas

  • Johns Hopkins University

    Baltimore, Maryland

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company - Kansas City, MO at St. Joseph Medical Center

    Kansas City, Missouri

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • Multicare Health System Tacoma General Hospital

    Tacoma, Washington

  • University of Wisconsin Cancer Center

    Madison, Wisconsin

  • Flinders Medical Centre

    Bedford Park, Australia

  • Sunshine Hospital - PARENT

    Footscray, Australia

  • Ashford Cancer Centre Research

    Kurralta Park, Australia

  • Liverpool Hospital - PARENT

    Liverpool, Australia

  • Calvary Mater Newcastle - PARENT

    Newcastle, Australia

  • Tasman Oncology Research Ltd - Oncology

    Southport, Australia

  • Macquarie University Hospital - PARENT

    Sydney, Australia

  • The Kinghorn Can Cen

    Westmead, Australia

  • ZNA Middelheim - Middelheim - account 2

    Antwerp, Belgium

  • AZ Klina - PARENT

    Brasschaat, Belgium

  • Institut Jules Bordet - Medical Oncology

    Brussels, Belgium

  • Universitair Ziekenhuis Gent - Medical Oncology

    Ghent, Belgium

  • AZ Groeninge - Campus Kennedylaan - account 2

    Kortrijk, Belgium

  • Centre Hospitalier de l'Ardenne - PARENT

    Libramont, Belgium

  • CHU de Liège - PARENT

    Liège, Belgium

  • Universitaetsklinikum Wuerzburg - Klinik u. Poliklinik f. Urologie u. Kinderurologie

    Wuerzburg, Belgium

  • William Osler Health System - Brampton Civic Hospital

    Brampton, Canada

  • CISSS de la Monteregie-Centre - Hospital Charles Le Moyne

    Greenfield Park, Canada

  • CHUM Centre de Recherche

    Montreal, Canada

  • The Ottawa Hospital Cancer Centre

    Ottawa, Canada

  • ICO - Site Paul Papin - service d'oncologie medicale

    Angers, France

  • Institut Bergonié - Service d'Oncologie Médicale

    Bordeaux, France

  • Centre François Baclesse - Pathologies Gynecologiques

    Caen, France

  • Hôpital Henri Mondor - Service d'Oncologie Médicale

    Créteil, France

  • Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical

    Le Mans, France

  • Centre Leon Berard - Service d'Oncologie Medicale

    Lyon, France

  • Hôpital de la Timone - service d'urologie

    Marseille, France

  • Hopital Caremeau - Service Hématologie Clinique/Oncologie Médicale

    Nîmes, France

  • Hôpital Cochin - Hematologie et Oncologie Médicale

    Paris, France

  • CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale

    Poitiers, France

  • CRLCC Eugene Marquis - Service d'Oncologie médicale

    Rennes, France

  • ICO - Site René Gauducheau - Service d'Oncologie medicale

    Saint-Herblain, France

Showing 40 of 98 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.